New Rules, Ministry Of Health Allows Vaccine Program To Use A Brand Similar To Gotong Royong Vaccine

JAKARTA - The Ministry of Health (Kemenkes) now allows the national program COVID-19 vaccination to use the same brand or type of vaccine as the Gotong Royong vaccine.

Currently, Gotong Royong vaccination uses Sinopharm and Cansino brand vaccines. Both are from Chinese companies.

This provision is contained in Minister of Health Regulation (PMK) Number 18 of 2021 which was ratified by the Minister of Health (Menkes) on May 28, 2021, replacing Permenkes Number 10 of 2021.

"In this new PMK, the Ministry of Health allows the use of the same type of COVID-19 vaccine between the government vaccination program and the Gotong Royong vaccination, provided that the type of COVID-19 vaccine for the Vaccination Program is obtained from grants, donations, or gifts from both the community and the community. other countries," said Head of the Ministry of Health's Communication and Public Service Bureau, Widyawati in a statement, Monday, June 14.

The COVID-19 vaccine in question is also not for sale. Then, must be given a special sign that can be recognized by naked eye.

Widyawati said, changes to the rules regarding the implementation of vaccinations in the context of dealing with the COVID-19 pandemic to increase the coverage of the national vaccination program.

In addition, PMK Number 18 of 2021 also regulates the handling of Post-vaccination Adverse Events (AEFI) of COVID-19 that requires treatment and care at health facilities in accordance with medical indications and treatment protocols.

In the financing aspect, active participants of the National Health Insurance (JKN) will be covered through the JKN mechanism and can be carried out in all health care facilities (fasyankes).

"For non-active participants and not JKN participants, they will be funded through other funding mechanisms sourced from the state revenue and expenditure budget in accordance with statutory provisions," he said.

The health services to be provided are equivalent to class III of the National Health Insurance Program or above class III at their own will with the difference in costs borne by the person concerned.

"The update of this provision is an effort from the Ministry of Health as the organizer of the national vaccination program to accelerate vaccination activities in order to achieve group immunity by continuing to pay attention to the need for COVID-19 vaccination in Indonesia," he concluded.